Mesothelioma.com Resources for Patients and their Families

Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies

Brief Summary

This is a single arm, open-label, uni-center, phase I-II study to evaluate the safety and effectiveness of CAR-T/TCR-T cell immunotherapy in treating with different malignancies patients.

Tracking Information
First Received DateAugust 16, 2018
Last Changed DateAugust 17, 2018
Start DateMarch 1, 2018
Anticipated Primary Completion DateMarch 1, 2023
Primary Outcome Measures

Number of Participants With Adverse Events evaluated with NCI CTC AE, version 4.0 [Time Frame: 60 months]

Secondary Outcome Measures

Clinical response [Time Frame: 60 months]

CAR-T cells testing [Time Frame: 60 months]

Descriptive Information
PhasePhase 1/Phase 2
Study TypeInterventional
Condition
  • B-cell Acute Lymphoblastic Leukemia
  • Lymphoma
  • Myeloid Leukemia
  • Multiple Myeloma
  • Hepatoma
  • Gastric Cancer
  • Pancreatic Cancer
  • Mesothelioma
  • Colorectal Cancer
  • Esophagus Cancer
  • Lung Cancer
  • Glioma
  • Melanoma
  • Synovial Sarcoma
  • Ovarian Cancer
  • Renal Carcinoma
Intervention
  • Biological: CAR-T cell immunotherapy
Study Arms / Comparison Groups1 / 0
Detailed Description

The study is a multi-target gene-modified immunotherapy. CAR-T/TCR-T cells include ten different tumor-specific antibody.They are as following:anti-CD19 antibody for B cell leukemia and lymphoma;anti-CD22 antibody for B cell leukemia and lymphoma;anti-CD33 antibody for myeloid leukemia;anti-BCMA antibody for multiple myeloma;anti-CD38 antibody for multiple myeloma;anti-NY-ESO-1 antibody for multiple myeloma,esophagus cancer,lung cancer,melanoma and synovial sarcoma;anti-DR5 antibody for hepatoma;anti-C-met antibody for hepatoma,colorectal cancer,ovarian cancer and renal carcinoma;anti-EGFR V III antibody for hepatoma,lung cancer and glioma;anti-Mesothelin antibody for gastric cancer,pancreatic cancer and mesothelioma.

Recruitment Information
Recruitment StatusRecruiting
Anticipated Enrollment73
GenderAll
Ages4 Years - 70 Years
Accepts Healthy VolunteersNo
Contact ZhongHua Yang
Email: zh.yang@bindebio.com
Phone: 18938688105
Eligibility Criteria

Inclusion Criteria:

1. If patients had receive immunotherapy, they should reach PR/NR, or recurrency.

2. Patients must be willing to sign an informed consent.

3. age: 4 to 70 years

4. Estimated survival of ≥ 12 weeks, but ≤ 2 years

5. Blood tumor or solid tumor was diagnosed by histopathology.Positive expression of CD19, CD22, CD33, CD38, BCMA, NY-ESO-1, c-met, Mesothelin, CEGFRvIII and DR5 was confirmed by biopsy IHC test or flow cytometry test. If NY-ESO-1 is positive expression ,positive HLA-A*0201 is required at the same time .

6. Subjects with solid tumor must have measureable disease

7. Routine blood test:hemoglobin>=90 g/L; platelet>=50×10^9/L.

8. Renal function:BUN: 9-20mg / dl; serum creatinine<= 1.5 times upper limits of normal; endogenous creatinine clearance rate>=50 ml/min

9. Negative serum antibody for EBV, CMV, HIV , syphilis, HBVa nd HCV(patients with liver cancer were excluded)

10. Cardiac function: stable hemodynamic and left ventricular ejection fraction (LVEF)>=55%.

11. ECOG score ≤2

12. Adequate venous access for apheresis, and no other contraindications for leukapheresis

13. Women of child-bearing age must have evidence of negative pregnancy test.

14. Subjects of reproductive potential must agree to use acceptable birth control methods within 1 year after treatment, as described in protocol.

Exclusion Criteria:

1. ECOG >= 3

2. Patients with history of T cell tumors

3. Patients with severe insufficient cardiac, pulmonary and hepatorenal functions

4. Acute or chronic GVHD after allogeneic hematopoiesis

5. steroid hormoneswere used before and after blood collection and infusion

6. HIV infection or active hepatitis B or hepatitis C infection

7. Uncontrolled active infection

8. Enrolled to other clinical study in the last 4 weeks.

9. Subjects with systemic auto-immune disease or immunodeficiency.

10. Subjects with CNS diseases.

11. Other patients that researchers considered unsuitable for inclusion

Administrative Information
NCTIDNCT03638206
Responsible PartySponsor
SponsorShenzhen BinDeBio Ltd.
Verification DateAugust 2018
Share
Tweet
Share
Mesothelioma Treatment Guide

Free Mesothelioma Treatment Guide

Please fill in the form below to request our FREE Mesothelioma Treatment Guide. It will be sent to you within 24 hours.

Have you or someone you know been diagnosed with mesothelioma?

Get Access To: